TME Pharma N.V. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was EUR 3.66 million compared to EUR 10.33 million a year ago. Basic loss per share from continuing operations was EUR 1.09 compared to EUR 11.47 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.249 EUR | +0.20% | -0.99% | +8.26% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.26% | 7.56M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023